1104502--4/20/2009--ACRONGENOMICS

related topics

{stock, price, share}

{interest, director, officer}

{condition, economic, financial}

{investment, property, distribution}

{acquisition, growth, future}

{property, intellectual, protect}

{product, market, service}

{financial, litigation, operation}

Risks Related to our Company The global financial crisis has had, and may continue to have, an impact on our business and financial condition. We have not earned any revenues since our incorporation and only have a limited operating history in our current business, which raise doubt about our ability to continue as a going concern. Our Share Exchange Agreement with Vardisto Investments Limited may not be completed and we may not obtain an interest in the development of the potential cholesterol-lowering agent. Even if we do obtain an interest in the potential cholesterol-lowering agent, there is no assurance that it will ever become commercially viable. We may never develop and commercialize any products. If this happens we will not become profitable and we will go out of business. Risks Related to our Business Our likelihood of profit depends on our ability to obtain, develop and market a profitable life science technology. We currently do not have such a technology. If we are unable to obtain such a technology and successfully sell it, our company will likely fail and investors will lose their entire investment in our company. We need to raise additional financing to support the research and development of future business but we cannot be sure that we will be able to obtain additional financing on terms favorable to us when needed. If we are unable to obtain additional financing to meet our needs, our operations may be adversely affected or terminated. We may be subject to intellectual property litigation such as patent infringement claims, which could adversely affect our business. Potential product liability claims could adversely affect our future earnings and financial condition. Because some of our officers and directors are located in non-U.S. jurisdictions, you may have no effective recourse against the management for misconduct and may not be able to enforce judgment and civil liabilities against our officers, directors, experts and agents. If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted. Investment Company Act of 1940 Risks Related to our Common Stock The recent weakening of economic conditions around the world could have harmful effects on our company. If these harmful effects cause us to cease our development of medical technologies, then our shareholders will likely lose their entire investment in our company. Because we do not intend to pay any dividends on our common stock, investors seeking dividend income or liquidity should not purchase shares of our common stock. If we issue additional shares in the future, it will result in the dilution of our existing shareholders. Our stock is considered a penny stock and certain securities rules may hamper the tradability of our shares in the market. The Financial Industry Regulatory Authority, or FINRA, has adopted sales practice requirements which may also limit a stockholder's ability to buy and sell our stock.

Full 10-K form ▸

1104502--4/20/2009--ACRONGENOMICS_INC